Zander Therapeutics, Inc.
4700 Spring Street
Suite 304
La Mesa
California
91942
United States
Tel: 619-702-1404
Fax: 619-330-2328
Website: http://www.zandertherapeutics.com/
About Zander Therapeutics, Inc.
Zander Therapeutics, Inc. is a veterinary biotechnology company that is wholly owned by Entest BioMedical Inc. (a publicly traded company -- OTCPINK: ENTB). Zander is focused on developing veterinary treatments for cancer and autoimmune disorders (such as arthritis). We are targeting canine cancer, especially considering that 50% of all dogs over the age of 10 years will develop some form of cancer. Feline Leukemia (FL) is another focal point, with 2-3% of all cats in the United States carrying the feline leukemia virus. Additionally, we are looking at arthritis in animals from dogs and cats to thoroughbred horses. LEADERSHIP:CEO: David R. Koos
CSO: Harry Lander
CFO: Todd S. Caven
JOBS:
Please click here for Zander Therapeutics job opportunities.
12 articles about Zander Therapeutics, Inc.
-
Entest Group, Inc. Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.
5/10/2018
Entest Group, Inc. (OTC: ETNI) declared the distribution on a pro rata basis as a dividend in kind of 3,000,000...
-
Entest Biomedical, Inc. Announces 3 Million Share Zander Therapeutics, Inc. Dividend To Be Paid To Shareholders
9/29/2017
-
Zander Therapeutics, Inc. Announces Appointment Of Dr. Robin Beat Gasser To Scientific Advisory Board
9/13/2017
-
Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression Of IL-17a And IL-2 In Dogs With Novel NR2F6 Activators
7/26/2017
-
Zander Therapeutics, Inc. Announces Brian Devine, Former Chairman Of PETCO, To Helm Its Business Advisory Board
6/27/2017
-
Entest Biomedical, Inc.'s Subsidiary Zander Therapeutics, Inc., Reports Its Series A Compounds Suppressed The Production Of Multiple Cytokines Known To Be Involved In Inflammation With No Toxicity In Canine Studies
6/14/2017
-
Entest Biomedical, Inc.'s Subsidiary EnteroMedics Reports On Preliminary Canine Experiments Testing New Anti-Inflammatory Drug Compounds
6/7/2017
-
Entest Biomedical, Inc. Subsidiary Zander Therapeutics, Inc. Discusses Developments In Medicinal Chemistry For Veterinary Applications Of Cancer And Autoimmune Therapies Through Modulation Of Checkpoint NR2F6
5/24/2017
-
Entest Biomedical, Inc.'s Chairman Discusses Its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies For Treating Cancer And Arthritis In Dogs
4/27/2017
-
Entest Biomedical, Inc.'s Subsidiary, Zander Therapeutics, Inc., Initiates Ex Vivo Studies On Modulating NR2F6 In Canines
4/19/2017
-
Entest Biomedical, Inc.'s Subsidiary Zander Therapeutics, Inc. Announces Appointment Of Dr. Thomas Donnelly To Serve As Senior Veterinary Advisor
3/9/2017
-
Entest Biomedical, Inc.'s Zander Therapeutics, Inc. Unit Announces Publication Of Canine Cellular Immunotherapy Patent Application For Treating Cancer In Dogs
2/15/2017